{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.369","value":"44.44"},{"groupId":"OG001","spread":"24.085","value":"63.25"},{"groupId":"OG002","spread":"26.981","value":"60.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"comment":"NA: data not available due to below the level of detection and insufficient number of participants with events.","groupId":"OG000","spread":"NA","value":"0"},{"groupId":"OG001","spread":"8.740","value":"54.17"},{"groupId":"OG002","spread":"21.973","value":"46.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Cycle 23"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"23.750","value":"50.00"},{"groupId":"OG002","spread":"23.750","value":"50.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Cycle 32"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"description":"EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale (Global Health Status). EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all \\[best\\] to 4=Very Much \\[worst\\]) and 2 questions (7-point scale where 1=Very poor \\[worst\\] to 7= Excellent \\[best\\]). Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL.","dispersionType":"Standard Deviation","groups":[{"description":"Bortezomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG000","title":"[VRd]; Bortezomib + Lenalidomide + Dexamethasone Therapy"},{"description":"Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG001","title":"[KRd]; Carfilzomib + Lenalidomide + Dexamethasone Therapy"},{"description":"Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG002","title":"[Overall]; Combination Therapy + Ixazomib Therapy"}],"paramType":"MEAN","populationDescription":"Full Analysis Set (FAS): all participants who were enrolled in Treatment Period I and who receive at least one dose of any therapy during the Treatment Period.","reportingStatus":"POSTED","timeFrame":"Baseline and End of Treatment (Up to 23 cycles for VRd Group, Up to 32 cycles for KRd and Overall Group, each cycle was of 28 days)","title":"Patient-Reported Outcome Health-Related Quality of Life (HRQoL) Based on Global Health Status Scale of European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30)","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}